Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Pfizer's Paxlovid has become the first oral antiviral for COVID-19 to be authorised for emergency use by the FDA, as the US braces itself for a surge in Omicron cases over the holiday period.

Also Read: Pfizer's Paxlovid Demonstrates Safety But ... that traditional medical records may overlook. Extended antiviral courses have precedent in other conditions like HIV and hepatitis C ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

He pointed to the company’s ability not only to develop a Covid vaccine from a standing stop, but also its unique success in creating Paxlovid, a Covid antiviral. “Pfizer is the same company ...

McAdam LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.2% in the fourth quarter, according ...

Just over a year later, Pfizer expanded the partnership to antivirals and cancer drugs, paying PostEra $13 million up front and promising up to $248 million in milestone payments. The new deal ...

Burford Brothers Inc. decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 10.6% in the fourth quarter, ...